Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Andrew Satlin"'
Autor:
Trisha Suppes, Suresh Durgam, Susan G. Kozauer, Richard Chen, Hassan D. Lakkis, Robert E. Davis, Andrew Satlin, Kimberly E. Vanover, Sharon Mates, Roger S. McIntyre, Mauricio Tohen
Publikováno v:
Bipolar Disorders.
Autor:
Kimberly E. Vanover, Joseph R. Calabrese, Robert E. Davis, Andrew Satlin, Gary S. Sachs, Richard Chen, Suresh Durgam, Susan Kozauer, Sharon Mates
Publikováno v:
The American journal of psychiatry. 178(12)
In a phase 3 randomized double-blind placebo-controlled study, the authors investigated the efficacy and safety of 42 mg/day of lumateperone in patients with bipolar I or bipolar II disorder experiencing a major depressive episode.Patients 18-75 year
Autor:
Kimberly E. Vanover, Sharon Mates, John M. Kane, Andrew Satlin, Richard Chen, Robert C. Davis, Suresh Durgam
Publikováno v:
International Clinical Psychopharmacology
Supplemental Digital Content is available in the text.
Lumateperone, an antipsychotic that is US Food and Drug Administration-approved for the treatment of schizophrenia, has a novel mechanism of action that may confer beneficial effects with im
Lumateperone, an antipsychotic that is US Food and Drug Administration-approved for the treatment of schizophrenia, has a novel mechanism of action that may confer beneficial effects with im
Autor:
Robert E. Davis, Kimberly E. Vanover, Sharon Mates, Christoph U. Correll, Andrew Satlin, Richard Chen
Publikováno v:
Schizophrenia research. 228
Lumateperone is a mechanistically novel agent FDA-approved for the treatment of schizophrenia. Efficacy and favorable tolerability of lumateperone were demonstrated in 2 short-term placebo-controlled studies in patients with schizophrenia. This open-
Autor:
Tim Abrahamsen, Christina L. Fanola, Steven R. Smith, Carlos Perdomo, Erin A. Bohula, Wenfeng Miao, Stephen D. Wiviott, Silvio E. Inzucchi, Anthony C Keech, Benjamin M. Scirica, Darren K. McGuire, Andrew Satlin, Marc S. Sabatine, Bruce Francis
Publikováno v:
American Heart Journal. 202:39-48
Objectives Lorcaserin, a selective serotonin 2C receptor agonist, is an effective pharmacologic weight-loss therapy that improves several cardiovascular risk factors. The long-term clinical cardiovascular and metabolic safety and efficacy in patients
Autor:
Quan Hong, Andrew Satlin, Margaret Moline, Patricia Murphy, Shobha Dhadda, David Mayleben, Russell Rosenberg, Luigi Giorgi, Gary Zammit, Kate Pinner
Publikováno v:
Journal of Clinical Sleep Medicine. 13:1289-1299
To identify dose(s) of lemborexant that maximize insomnia treatment efficacy while minimizing next-morning residual sleepiness and evaluate lemborexant effects on polysomnography (PSG) measures (sleep efficiency [SE], latency to persistent sleep [LPS
Autor:
Lisa J. Bain, Zahinoor Ismail, Heidi Jurgens, Pierre N. Tariot, Erik S. Musiek, Maria C. Carrillo, Ricardo S. Osorio, David Miller, Sonia Ancoli-Israel, Paul B. Rosenberg, Andrew Satlin, Brendon P. Boot, Clive Ballard, Krista L. Lanctôt, David C. Steffens, Jiska Cohen-Mansfield, James Hendrix, Constantine G. Lyketsos, Steven E. Arnold, Joan Amatniek
Publikováno v:
Lanctôt, K L, Amatniek, J, Ancoli-Israel, S, Arnold, S E, Ballard, C, Cohen-Mansfield, J, Ismail, Z, Lyketsos, C, Miller, D S, Musiek, E, Osorio, R S, Rosenberg, P B, Satlin, A, Steffens, D, Tariot, P, Bain, L J, Carrillo, M C, Hendrix, J A, Jurgens, H & Boot, B 2017, ' Neuropsychiatric signs and symptoms of Alzheimer's disease : New treatment paradigms ', Alzheimers & Dementia, vol. 3, no. 3, pp. 440-449 . https://doi.org/10.1016/j.trci.2017.07.001
Alzheimer's & dementia (New York, N. Y.), vol 3, iss 3
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Alzheimer's & dementia (New York, N. Y.), vol 3, iss 3
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptom
Autor:
Andrew Satlin, Sharon Mates, Robert C. Davis, Christoph U. Correll, William Rowe, Suresh Durgam, Kimberly E. Vanover
Publikováno v:
CNS Spectrums. 25:317-318
Introduction:Lumateperone (lumateperone tosylate, ITI-007) is an investigational drug for the treatment of schizophrenia, bipolar depression, and other disorders. Lumateperone has a unique mechanism of action that simultaneously modulates serotonin,
Autor:
William Rowe, Sharon Mates, John M. Kane, Suresh Durgam, Robert C. Davis, Andrew Satlin, Kimberly E. Vanover, Carol A. Tamminga
Publikováno v:
CNS Spectrums. 25:316-317
Introduction:Lumateperone (ITI-007) is in late-phase clinical development for schizophrenia. Lumateperone has a unique mechanism of action that modulates serotonin, dopamine, and glutamate neurotransmission. This pooled analysis of lumateperone in 3
Autor:
Michal Weingart, Juan Sanchez, Saresh Durgam, Susan Kozauer, Andrew Satlin, Shawon Hossain, Sharon Mates, Robert C. Davis, Jelena Saillard, Kimberly E. Vanover, Steven Glass
BACKGROUND: Lumateperone (ITI-007) is an investigational drug for the treatment of schizophrenia, bipolar depression, agitation associated with dementia and other neuropsychiatric disorders. With a unique mechanism of action, lumateperone modulates s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce5543dd3d23362ac43581f9ddf5ab39
https://europepmc.org/articles/PMC6455296/
https://europepmc.org/articles/PMC6455296/